Kivu Bioscience
San Francisco, California, United States · Biotechnology, Health Care · 9 employees
Kivu Bioscience is pioneering next-generation antibody-drug conjugates (ADCs) in oncology. The company’s proprietary linker-payload technology delivers enhanced safety and efficacy, minimizing off-target effects to improve patient outcomes. Kivu is advancing its first two lead candidates to clinical trials expected to begin in 2025.
Funding history
- Series series a — $92.0M — Oct 2024
Recent signals
- Mar 03, 2026: Kivu Bioscience Appoints Brunilda Shtylla as Chief Business Officer
- Oct 27, 2025: Kivu Bioscience Appoints Sophia Randolph as Chief Medical Officer
- Jun 02, 2025: Kivu Bioscience partners with Sterling Pharma Solutions for cGMP manufacturing of KIVU-107.
- Oct 28, 2024: Raised $92.0M in Series series a
See plans & pricing → Track Kivu Bioscience’s funding, hiring, and signals — with verified contacts — on Fundz.